Clinical Trials Logo

Anticoagulant Reversal clinical trials

View clinical trials related to Anticoagulant Reversal.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01826266 Completed - Clinical trials for Anticoagulant Reversal

Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

PER977-P1
Start date: July 2013
Phase: Phase 1
Study type: Interventional

PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers. A dose of PER977 that reverses the effects of edoxaban on the pharmacodynamic (PD) biomarkers (point of care prothrombin time [PoC-PT]), and/or secondary biomarkers (thromboelastography reaction time [TEG-R]) will be identified.